Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer (LS2 Trial)

N/A

Waitlist Available

Led By Sarah Ferguson, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be 18-70 years old

Patients must have endometrial cancer (all grades, stages and histologic subtypes except stromal sarcoma, carcinosarcoma)

Must not have

Patients must not be under 18 years old or over 70 years old

Patients must not have uterine adenosarcoma, leiomyosarcoma or endometrial stromal sarcoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

Awards & highlights

No Placebo-Only Group

Summary

This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.

Who is the study for?

This trial is for women aged 18-70 in Canada with endometrial cancer (excluding certain types) diagnosed within the last 6 months. Participants must have tumor tissue available and be able to consent. Their adult first-degree relatives can join if they give consent and live in Canada.

What is being tested?

The study tests an enhanced screening strategy for Lynch Syndrome among women with specific cancers, offering genetic counseling and testing. It also evaluates adherence to recommended guidelines over ten years after a Lynch Syndrome diagnosis.

What are the potential side effects?

Since this trial involves questionnaires and educational materials rather than medical treatments, traditional side effects are not expected. However, participants may experience stress or anxiety related to learning about their genetic risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 70 years old.

Select...

I have endometrial cancer, but it's not stromal sarcoma or carcinosarcoma.

Select...

My cancer tissue is available for a specific protein test.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am between 18 and 70 years old.

Select...

My cancer is not uterine adenosarcoma, leiomyosarcoma, or endometrial stromal sarcoma.

Select...

My ovarian cancer is not purely serous or mucinous.

Select...

I cannot or do not want to give informed consent.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

This trial's timeline: 3 weeks for screening, Varies for treatment, and short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis for reporting.